242 related articles for article (PubMed ID: 34034807)
21. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
23. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.
Favre L; Cohen J; Calderaro J; Pécriaux A; Nguyen CT; Bourgoin R; Larnaudie L; Dupuy A; Ollier M; Lechapt E; Sloma I; Tournigand C; Rousseau B; Pujals A
Mol Oncol; 2022 Sep; 16(17):3055-3065. PubMed ID: 35624529
[TBL] [Abstract][Full Text] [Related]
25. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
26. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas.
Koinuma K; Shitoh K; Miyakura Y; Furukawa T; Yamashita Y; Ota J; Ohki R; Choi YL; Wada T; Konishi F; Nagai H; Mano H
Int J Cancer; 2004 Jan; 108(2):237-42. PubMed ID: 14639609
[TBL] [Abstract][Full Text] [Related]
27. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
28. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
[TBL] [Abstract][Full Text] [Related]
29. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
30. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Laskar RS; Ghosh SK; Talukdar FR
Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
[TBL] [Abstract][Full Text] [Related]
31. Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.
Lasabová Z; Kalman M; Holubeková V; Grendár M; Kašubová I; Jašek K; Meršaková S; Malicherová B; Baranenko D; Adamek M; Kruzliak P; Plank L
Clin Exp Med; 2019 Aug; 19(3):393-400. PubMed ID: 31049795
[TBL] [Abstract][Full Text] [Related]
32. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
33. Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report.
Zohud BA; Wang M; Cai X
BMC Gastroenterol; 2020 Aug; 20(1):255. PubMed ID: 32758138
[TBL] [Abstract][Full Text] [Related]
34. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer.
Snahnicanova Z; Kasubova I; Kalman M; Grendar M; Mikolajcik P; Gabonova E; Laca L; Caprnda M; Rodrigo L; Ciccocioppo R; Kruzliak P; Plank L; Lasabova Z
Clin Exp Med; 2020 Feb; 20(1):87-95. PubMed ID: 31853669
[TBL] [Abstract][Full Text] [Related]
36. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
37. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
[TBL] [Abstract][Full Text] [Related]
39. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
40. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
